WebJan 15, 2024 · AGO-OVAR 12 investigated the effect of adding the oral triple angiokinase inhibitor nintedanib to standard front-line chemotherapy for advanced ovarian cancer. At the primary analysis, nintedanib demonstrated significantly improved progression-free survival (PFS; primary endpoint) compared with plac … WebMay 26, 2024 · Methods: AGO-OVAR 2.29 is a randomized (1:1), double blinded, phase III trial evaluating the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy (weekly paclitaxel or pegylated liposomal doxorubicin) compared with placebo plus …
Performance of AGO score for secondary cytoreduction in
WebApr 4, 2024 · The researchers found mutations of the Fragile X messenger ribonucleoprotein 1 gene, or FMR1, contribute to premature ovarian failure, or POF, due to changes in … WebMay 28, 2024 · Background: GOG-0218 established the addition of BEV 15 mg/kg every 3 weeks (q3w) for 15 months to standard front-line chemotherapy for advanced ovarian cancer, but the optimal BEV duration remained unknown. We report primary results from a randomized phase 3 trial designed to address this question. 卵アレルギー 6ヶ月
Ago Definition & Meaning - Merriam-Webster
WebJun 15, 2024 · Finally, the AGO-DESKTOP III trial was designed to evaluate in a prospectively randomized multicenter setting whether SeCRS followed by platinum … WebDec 14, 2024 · Anzahl Pat. Gynäkologisch-Onkologische Praxis. Mind. 15 Pat. mit invasiven Neoplasien d. Genitals inkl. Borderlinetumore und seröse tubare intraepitheliale Car cinom e (STIC) /Jahr (primär u./o. palliativ) mit Diagnostik, Therapie u./ o. Nachsorge (entsprechend den Nachsorgeempfehlungen bis 5 J. nach Erstdiagnose) bd 取り込み